We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
By clicking "Allow All" you agree to the storing of cookies on your device to enhance site navigation, analyse site usage and support us in providing free open access scientific content. More info.
Albumedix, now part of the life sciences group Sartorius, is an innovation-focused biotechnology company based out of a purpose-built cGMP facility in Nottingham, UK. Albumedix is well recognized as a leader in albumin-enabled solutions.
Albumedix mission is dedicated to better health. Over nearly four decades of commitment, Albumedix has supported its partners to deliver safe doses globally, in both clinical development phase and marketed therapeutics, to millions of patients. Albumedix' portfolio of solutions includes the world's only USP-NF-compliant recombinant human albumin (Recombumin®); client-centric services, and proprietary drug-enhancing technology (Veltis®).
Nature, by evolution, has developed a versatile molecule, albumin, with unique characteristics and properties. Through revolutionary approaches, Albumedix has perfected what nature created to enable effective applications of albumin that support the development and commercialization of an array of life science products. These enhancements and the high levels of consistency Recombumin® offers overcomes the limitations that blood-derived albumin can present.